Intracellular delivery of full length recombinant human mitochondrial L-Sco2 protein into the mitochondria of permanent cell lines and SCO2 deficient patient's primary cells

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 6, 2010, Pages 497-508

  Foltopoulou, Parthena F ^a,b   Tsiftsoglou, Asterios S ^a   Bonovolias, Ioannis D ^a   Ingendoh, Alexandra T ^a   Papadopoulou, Lefkothea C ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Cytochrome c oxidase; Mitochondrion; Protein transduction; SCO2 Sco2

Indexed keywords

ARGININE; CYTOCHROME C OXIDASE; HYBRID PROTEIN; METHIONINE; RECOMBINANT FUSION L SCO2 PROTEIN; SULFUR 35; UNCLASSIFIED DRUG;

ARTICLE; CELL INCLUSION; CELL VIABILITY; CONTROLLED STUDY; CYTOCHROME C OXIDASE DEFICIENCY; DRUG SCREENING; EMBRYO; ENZYME ACTIVATION; EXPRESSION VECTOR; FIBROBLAST; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTRACELLULAR TRANSPORT; MEDICAL TECHNOLOGY; MITOCHONDRIAL MEMBRANE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSDUCTION TECHNOLOGY; TRANSPORT KINETICS;

AMINO ACID SEQUENCE; BASE SEQUENCE; CARRIER PROTEINS; CELL LINE; CELLS, CULTURED; CLONING, MOLECULAR; DNA PRIMERS; ELECTRON TRANSPORT COMPLEX IV; ESCHERICHIA COLI; HUMANS; K562 CELLS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MITOCHONDRIAL PROTEINS; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SOLUBILITY; TRANSDUCTION, GENETIC;

MAMMALIA;

EID: 77952236882     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.02.009     Document Type: Article

References (45)

1. Papadopoulou L.C., Sue C.M., Davidson M.M., Tanji K., Nishino I., Sadlock J.E., Krishna S., Walker W., Selby J., Glerum D.M., Coster R.V., Lyon G., Scalais E., Lebel R., Kaplan P., Shanske S., De Vivo D.C., Bonilla E., Hirano M., DiMauro S., Schon E.A. Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene. Nat. Genet. 1999, 23:333-337.
2. Salviati L., Sacconi S., Rasalan M.M., Kronn D.F., Braun A., Canoll P., Davidson M., Shanske S., Bonilla E., Hays A.P., Schon E.A., DiMauro S. Cytochrome c oxidase deficiency due to a novel SCO2 mutation mimics Werdnig-Hoffmann disease. Arch. Neurol. 2002, 59:862-865.
3. Foltopoulou P.F., Zachariadis G.A., Politou A.S., Tsiftsoglou A.S., Papadopoulou L.C. Human recombinant mutated forms of the mitochondrial COX assembly Sco2 protein differ from wild-type in physical state and copper binding capacity. Mol. Genet. Metab. 2004, 81:225-236.
4. Jaksch M., Paret C., Stucka R., Horn N., Muller-Hocker J., Horvath R., Trepesch N., Stecker G., Freisinger P., Thirion C., Muller J., Lunkwitz R., Rodel G., Shoubridge E.A., Lochmuller H. Cytochrome c oxidase deficiency due to mutations in SCO2, encoding a mitochondrial copper-binding protein, is rescued by copper in human myoblasts. Hum. Mol. Genet. 2001, 10:3025-3035.
5. Williams J.C., Sue C., Banting G.S., Yang H., Glerum D.M., Hendrickson W.A., Schon E.A. Crystal structure of human SCO1: implications for redox signaling by a mitochondrial cytochrome c oxidase "assembly" protein. J. Biol. Chem. 2005, 280:15202-15211.
6. Assaily W., Benchimol S. Differential utilization of two ATP-generating pathways is regulated by p53. Cancer cell 2006, 10:4-6.
7. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., Hurley P.J., Bunz F., Hwang P.M. p53 regulates mitochondrial respiration. Science 2006, 312:1650-1653.
8. DiMauro S., Hirano M., Schon E.A. Approaches to the treatment of mitochondrial diseases. Muscle Nerve 2006, 34:265-283.
9. Schwarze S.R., Ho A., Vocero-Akbani A., Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999, 285:1569-1572.
10. Gump J.M., Dowdy S.F. TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol. Med. 2007, 13:443-448.
11. Joliot A., Prochiantz A. Transduction peptides: from technology to physiology. Nat. Cell Biol. 2004, 6:189-196.
12. Patel L.N., Zaro J.L., Shen W.C. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm. Res. 2007, 24:1977-1992.
13. Popiel H.A., Nagai Y., Fujikake N., Toda T. Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice. Neurosci. Lett. 2008, 449:87-92.
14. Vives E. Present and future of cell-penetrating peptide mediated delivery systems: "is the Trojan horse too wild to go only to Troy?". J Control Release 2005, 109:77-85.
15. Rapoport M., Saada A., Elpeleg O., Lorberboum-Galski H. TAT-mediated delivery of LAD restores pyruvate dehydrogenase complex activity in the mitochondria of patients with LAD deficiency. Mol. Ther. 2008, 16:691-697.
16. Yamada Y., Akita H., Kogure K., Kamiya H., Harashima H. Mitochondrial drug delivery and mitochondrial disease therapy-an approach to liposome-based delivery targeted to mitochondria. Mitochondrion 2007, 7:63-71.
17. Fittipaldi A., Giacca M. Transcellular protein transduction using the Tat protein of HIV-1. Adv. Drug Deliv. Rev. 2005, 57:597-608.
18. Herrmann J.M., Funes S. Biogenesis of cytochrome oxidase-sophisticated assembly lines in the mitochondrial inner membrane. Gene 2005, 354:43-52.
19. Del Gaizo V., MacKenzie J.A., Payne R.M. Targeting proteins to mitochondria using TAT. Mol. Genet. Metab. 2003, 80:170-180.
20. Del Gaizo V., Payne R.M. A novel TAT-mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Mol. Ther. 2003, 7:720-730.
21. Dolezal P., Likic V., Tachezy J., Lithgow T. Evolution of the molecular machines for protein import into mitochondria. Science 2006, 313:314-318.
22. Chacinska A., Koehler C.M., Milenkovic D., Lithgow T., Pfanner N. Importing mitochondrial proteins: machineries and mechanisms. Cell 2009, 138:628-644.
23. Becker-Hapak M., McAllister S.S., Dowdy S.F. TAT-mediated protein transduction into mammalian cells. Methods (San Diego, Calif.) 2001, 24:247-256.
24. Vocero-Akbani A., Lissy N.A., Dowdy S.F. Transduction of full-length Tat fusion proteins directly into mammalian cells: analysis of T cell receptor activation-induced cell death. Methods Enzymol. 2000, 322:508-521.
25. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning, A Laboratory Manual 1989, CSH Laboratory Press.
26. Starosta-Rubinstein S., Ciliax B.J., Penney J.B., McKeever P., Young A.B. Imaging of a glioma using peripheral benzodiazepine receptor ligands. Proc. Natl. Acad. Sci. USA 1987, 84:891-895.
27. Kato T., Ishikawa K., Nemoto R., Senoo A., Amano Y. Morphological characterization of two established cell lines, T24 and MGH-U1, derived from human urinary bladder carcinoma. Tohoku J. Exp. Med. 1978, 124:339-349.
28. Knowles B.B., Howe C.C., Aden D.P. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980, 209:497-499.
29. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977, 36:59-74.
30. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975, 45:321-334.
31. Tsiftsoglou A.S., Hwang K.M., Agrawal K.C., Sartorelli A.C. Strand-scission of sarcoma 180 tumor cell DNA induced by 1-formylisoquinoline thiosemicarbazone. Biochem. Pharmacol. 1975, 24:1631-1633.
32. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162:156-159.
33. Church G.M., Gilbert W. Genomic sequencing. Proc. Natl. Acad. Sci. USA 1984, 81:1991-1995.
34. Tembe V., Henderson B.R. BARD1 translocation to mitochondria correlates with Bax oligomerization, loss of mitochondrial membrane potential, and apoptosis. J. Biol. Chem. 2007, 282:20513-20522.
35. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
36. Kirby Biochemical assays of respiratory chain complex activity. Methods in Cell Biology 2007, vol. 80:93-119.
37. Bonovolias I.D., Tsiftsoglou A.S. Hemin counteracts the repression of Bcl-2 and NrF2 genes and the cell killing induced by imatinib in human Bcr-Abl(+) CML cells. Oncol. Res. 2009, 17:535-547.
38. Schapira A.H. Mitochondrial disease. Lancet 2006, 368:70-82.
39. Dimauro S., Rustin P. A critical approach to the therapy of mitochondrial respiratory chain and oxidative phosphorylation diseases. Biochim. Biophys. Acta 2008, 1792:1159-1167.
40. Muratovska A., Lightowlers R.N., Taylor R.W., Wilce J.A., Murphy M.P. Targeting large molecules to mitochondria. Adv. Drug Deliv. Rev. 2001, 49:189-198.
41. Weissig V., Cheng S.M., D'Souza G.G. Mitochondrial pharmaceutics. Mitochondrion 2004, 3:229-244.
42. Hu Y., Suarez J., Fricovsky E., Wang H., Scott B.T., Trauger S.A., Han W., Hu Y., Oyeleye M.O., Dillmann W.H. Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose. J. Biol. Chem. 2009, 284:547-555.
43. Tsumoto K., Umetsu M., Kumagai I., Ejima D., Philo J.S., Arakawa T. Role of arginine in protein refolding, solubilization, and purification. Biotechnol. Prog. 2004, 20:1301-1308.
44. Koga Y., Akita Y., Nishioka J., Yatsuga S., Povalko N., Katayama K., Matsuishi T. MELAS and l-arginine therapy. Mitochondrion 2007, 7:133-139.
45. Kaul D.K., Zhang X., Dasgupta T., Fabry M.E. Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H39-H47.